Glucagon receptor agonist: signaling, retatrutide and evidence
What glucagon receptor agonism means, how retatrutide fits, and what human study designs can—and cannot—establish about signaling.
ALORA Research editorial teamPublished Last reviewed 6 min read
The short answer
A glucagon receptor agonist is a molecule that activates the glucagon receptor. Human trial reports describe retatrutide (LY3437943) as a single peptide that also activates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This establishes its multi-receptor classification, not the separate contribution of glucagon receptor activity to liver signaling or energy expenditure.
Key facts
- Research example
- Retatrutide (LY3437943), identified in a human trial report. [1]
- Molecular format
- A single peptide in the human phase 2 report. [2]
- Key distinction
- Glucagon and GLP-1 receptors are separate targets in the pharmacology review. [3]
- Liver-focused evidence
- Randomized, double-blind, placebo-controlled human substudy. [4]
- Additional study design
- Randomized, double-blind, placebo-controlled human phase 3 study. [5]
- Catalog code
- ALO-P-003
- Molecular formula
- C223H343F3N48O64
- Molecular weight
- 4731.3 g/mol
- Classification
- Research peptide — laboratory use only
What is a glucagon receptor agonist?
A glucagon receptor agonist is a molecule that activates the glucagon receptor. An agonist is the activating molecule; a receptor is its molecular target. Agonism names that activating activity, rather than a particular experimental result.
Terminology at a glance
- Glucagon: the hormone name associated with the glucagon receptor in the human retatrutide report's receptor classification. [1]
- Glucagon receptor (GCGR): a receptor target listed separately from the GLP-1 receptor in the pharmacology review. [3]
- Glucagon-like peptide-1 receptor (GLP-1R): the receptor associated with GLP-1, not another name for GCGR. [3]
- Glucose-dependent insulinotropic polypeptide receptor (GIP receptor): another receptor target named in the human retatrutide reports. [1, 2]
The distinction matters when reading about a multi-agonist, meaning a molecule with activating activity at multiple receptor targets. In human trial reports, retatrutide is described as having activity at GIP, GLP-1 and glucagon receptors. [1, 2] Consequently, the glucagon receptor agonist label describes part of its reported receptor profile, not its entire profile. [1, 2]
Keep the hormone name, receptor name and study compound separate when interpreting a mechanism claim.
Is retatrutide a glucagon receptor agonist?
Human trial reports identify retatrutide, also called LY3437943, as a glucagon receptor agonist with additional GIP and GLP-1 receptor activity. [1, 2]
The human phase 2 report by Rosenstock and colleagues specifically describes retatrutide as a single peptide with activity at these receptor targets. [2] This is a molecular classification, rather than a description of separate compounds combined in the study. [2] For the catalog identity, see the Retatrutide catalog record.
The pharmacology review places retatrutide within research on compounds with different receptor combinations and identifies its simultaneous glucagon and GLP-1 receptor activation. [3] That review supports the multi-receptor research context, but its abstract does not provide a receptor-specific energy-expenditure experiment. [3]
The human trial abstracts likewise do not report receptor-binding measurements or comparative receptor-activation measurements that quantify retatrutide's relative activity at each target. [1, 2] A named receptor profile therefore should not be read as a numerical ranking of receptor activity. For related terminology, see What is a GIP receptor agonist?.
What does the liver-focused research establish?
The human liver-focused retatrutide publication describes a randomized comparative substudy, not a liver-cell signaling experiment. [4]
Hepatic means relating to the liver. Intracellular signaling means the processes through which a signal is conveyed within a cell. These terms distinguish a mechanistic question from the broader description of a liver-focused study.
Sanyal and colleagues report a randomized, double-blind, placebo-controlled human substudy involving 98 participants over 48 weeks. [4] Its abstract does not describe receptor-selective laboratory comparisons, receptor-disruption experiments or measurements tracing a GCGR signaling pathway. [4]
The distinction limits what can be concluded from that publication's abstract: it supports the existence and design of the human substudy, but not a stepwise diagram of glucagon receptor signaling in liver cells. [4] It also does not establish which part of retatrutide's combined receptor activity accounts for a hepatic mechanism. [4]
Absence from an abstract does not prove that an experiment was never performed. It does mean that the abstract alone cannot document that experiment.
Which study designs are documented?
The primary retatrutide publications describe human comparative studies with placebo or active comparators, rather than experiments isolating GCGR activity. [1, 2, 4, 5]
Randomized means assignment used a chance-based process. Double-blind indicates masking of study assignment. An active comparator is another study compound, whereas a placebo comparator serves a different control role.
| Publication and experimental system | Comparator | Design or observation period reported | Mechanistic limit of the abstract |
|---|---|---|---|
| Jastreboff et al.; human phase 2 study | Placebo | Randomized, double-blind; 338 adults; 48 weeks. [1] | No isolated GCGR signaling experiment described. [1] |
| Rosenstock et al.; human phase 2 study | Placebo and dulaglutide | Randomized, double-blind, parallel-group; endpoints at 24 weeks and 36 weeks. [2] | No GCGR-selective comparison described. [2] |
| Sanyal et al.; human liver-focused substudy | Placebo | Randomized, double-blind; 98 participants; 48 weeks. [4] | No intracellular GCGR pathway measurements described. [4] |
| Bajaj et al.; human phase 3 study | Placebo | Randomized, double-blind; 40-week study; 537 participants randomly assigned. [5] | No receptor-disruption experiment described. [5] |
The evidence distinction is between a comparison involving a multi-receptor compound and a comparison that experimentally separates its receptor activities. In the human studies above, the abstracts describe the former, not the latter. [1, 2, 4, 5]
For a separate discussion of clinical study records, see Retatrutide trials: design, status and registry dates.
Can experiments isolate retatrutide's glucagon receptor activity?
The human retatrutide abstracts do not describe experiments that isolate its glucagon receptor activity from its other receptor activities. [1, 2]
A receptor-selective control focuses a comparison on a specified receptor. Receptor disruption means experimentally disabling receptor activity. These terms identify different kinds of mechanistic evidence from a comparison between complete study compounds.
In the human phase 2 study by Rosenstock and colleagues, dulaglutide was an active comparator alongside placebo. [2] The abstract also identifies retatrutide as active at GIP, GLP-1 and glucagon receptors, but does not describe a GCGR-selective control or receptor-disruption experiment. [2]
Accordingly, that reported design does not establish an isolated contribution from glucagon receptor activity. [2] The placebo-controlled human study by Jastreboff and colleagues likewise does not report a comparison that separates retatrutide's receptor activities. [1]
Read a comparison involving a multi-receptor peptide as a compound-level comparison unless receptor-isolating experiments are explicitly documented.
What remains unknown about energy expenditure?
The Jastreboff and Sanyal human trial abstracts do not establish a GCGR-specific energy-expenditure mechanism. [1, 4]
A direct measurement records the variable of interest; a biomarker is an indicator used to represent a biological process. Keep these categories distinct when evaluating an energy-expenditure hypothesis.
Neither human trial abstract reports direct energy-expenditure measurements or a biomarker analysis that establishes an isolated GCGR contribution to energy expenditure. [1, 4] The pharmacology review identifies combined receptor activation, but its abstract does not close this mechanistic gap. [3]
The supported conclusion is therefore narrower than a complete mechanism of action: human trial reports classify retatrutide as a multi-receptor agonist and document comparative study designs, without demonstrating the separate energy-expenditure contribution of its glucagon receptor activity. [1, 2, 4]
Keep analytical documentation separate from biological mechanism evidence as well. For lot-level certificates of analysis, see the COA library. Read those documents for their stated analytical scope, and read research publications for the experimental systems, controls and measurements they actually describe.
What the research establishes / What it does not establish
What the research establishes
- Human trial reports identify retatrutide (LY3437943) as an agonist of GIP, GLP-1 and glucagon receptors. [1, 2]
- The human phase 2 report by Rosenstock and colleagues describes retatrutide as a single peptide and includes placebo and dulaglutide comparators. [2]
- The pharmacology review distinguishes glucagon and GLP-1 receptor targets and identifies retatrutide as enabling their simultaneous activation. [3]
- The human liver-focused publication reports a randomized, double-blind, placebo-controlled substudy involving 98 participants over 48 weeks. [4]
What it does not establish
- A stepwise hepatic signaling pathway is not established by the human liver-focused substudy abstract, which does not report intracellular signaling experiments. [4]
- An isolated contribution from glucagon receptor activity is not established by the reported human comparisons of multi-receptor retatrutide with placebo or an active comparator. [1, 2]
- A GCGR-specific energy-expenditure mechanism is not established by the Jastreboff or Sanyal human trial abstracts; neither reports direct measurements establishing that mechanism. [1, 4]
Evidence at a glance
| Study | Year | Model | What was reported | Source |
|---|---|---|---|---|
| Jastreboff et al. | 2023 | Human study | The human phase 2 report identifies retatrutide as a GIP, GLP-1 and glucagon receptor agonist and describes a randomized, double-blind, placebo-controlled study involving 338 adults over 48 weeks. [1] | [1] |
| Rosenstock et al. | 2023 | Human study | The human phase 2 report describes retatrutide as a single multi-receptor peptide studied in a randomized, double-blind, parallel-group comparison with placebo and dulaglutide. [2] | [2] |
| Drucker | 2024 | Review | The pharmacology review distinguishes receptor combinations and identifies retatrutide as enabling simultaneous activation of glucagon and GLP-1 receptors. [3] | [3] |
| Sanyal et al. | 2024 | Human study | The human liver-focused publication describes a randomized, double-blind, placebo-controlled substudy involving 98 participants over 48 weeks, without reporting a GCGR-isolation experiment in its abstract. [4] | [4] |
| Bajaj et al. | 2026 | Human study | The human phase 3 report describes a 40-week randomized, double-blind, placebo-controlled study with 537 participants randomly assigned. [5] | [5] |
Frequently asked questions
What is a glucagon receptor agonist?
A glucagon receptor agonist is a molecule that activates the glucagon receptor. The pharmacology review distinguishes activation of this receptor from activation of the glucagon-like peptide-1 receptor. [3]
Is retatrutide a glucagon receptor agonist?
Yes: human trial reports identify retatrutide, also called LY3437943, as an agonist of glucagon, GLP-1 and GIP receptors. [1, 2] The human phase 2 report describes it as a single peptide, so its classification is multi-receptor rather than glucagon-receptor-selective. [2]
What is the difference between glucagon receptor agonism and GLP-1 receptor agonism?
The terms identify activation of different receptor targets, which the pharmacology review lists separately. [3] They are not mutually exclusive properties: human trial reports describe retatrutide as having activity at both receptors, alongside GIP receptor activity. [1, 2]
Does the liver-focused retatrutide study establish a glucagon receptor signaling mechanism?
The human liver-focused publication describes a randomized, double-blind, placebo-controlled substudy, but its abstract does not report a receptor-isolation experiment. [4] It therefore does not establish a stepwise intracellular pathway or identify an isolated GCGR contribution. [4]
Do the human trial abstracts establish a glucagon receptor energy-expenditure mechanism?
The Jastreboff and Sanyal human trial abstracts do not report direct energy-expenditure measurements establishing a GCGR-specific mechanism. [1, 4] Their descriptions of a multi-receptor compound and placebo-controlled designs should not be read as experimental isolation of glucagon receptor activity. [1, 4]
References
- 1.Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial The New England journal of medicine. 2023. PMID 37366315
- 2.Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Lancet (London, England). 2023. PMID 37385280
- 3.Drucker DJ Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity Diabetes care. 2024. PMID 38843460
- 4.Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Nature medicine. 2024. PMID 38858523
- 5.Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial Lancet (London, England). 2026. PMID 42250575
